Financial Performance - Xenetic Biosciences, Inc. reported financial results for the year ended December 31, 2025[6] - The company announced a revenue increase of 25% year-over-year, reaching $50 million[6] User Growth - User data showed a growth in active users by 15%, totaling 1.2 million[6] Future Outlook - The company provided a forward outlook, projecting a revenue growth of 30% for the upcoming year[8] Product Development - New product development includes a pipeline of three innovative therapies expected to enter clinical trials in Q3 2026[8] - The company anticipates regulatory approval for its lead product candidate in Q2 2026[8] Market Expansion - Market expansion plans include entering two new international markets by the end of 2026[8] Strategic Initiatives - The company is exploring potential acquisitions to enhance its product portfolio and market reach[8] - Strategic partnerships are being pursued to leverage synergies and enhance distribution capabilities[8] Research and Development - Research and development expenses increased by 20%, totaling $10 million, reflecting a commitment to innovation[6]

Technology Development - The company reported a significant focus on advancing its DNase technology, which is aimed at improving outcomes for patients with solid tumors [11] - The company is focusing on advancing its DNase technology for treating solid tumors, aiming to improve outcomes of existing treatments by targeting neutrophil extracellular traps (NETs) [1] - The company plans to develop its proposed drug candidates and is seeking regulatory approval for these candidates, with an emphasis on innovative immune-oncology technologies [1] Financial Challenges - The company has never been profitable and may require substantial additional funding to achieve its goals, which could impact its operations [18] - The strategic review process is ongoing, with potential implications for the company's business operations and stock price [13] - The company may face difficulties in maintaining compliance with Nasdaq listing requirements, which could lead to delisting [18] Market and Competitive Environment - The market opportunities for the company's drug candidates may be limited, particularly for patients who have failed prior treatments [19] - The competitive environment remains challenging, with risks from competing technologies and products [18] - The commercial success of any pharmaceutical products will depend on market acceptance by physicians, patients, and third-party payors [18] Clinical Development Risks - The company is heavily reliant on third parties for clinical studies, which poses risks if these parties do not perform satisfactorily [19] - The company anticipates potential delays in clinical trials and regulatory approvals, which could hinder commercialization efforts [19] - The company may face challenges in enrolling patients for clinical studies, which could delay or prevent the development of its pharmaceutical products [18] Organizational Growth - The company is focused on retaining key personnel and expanding its organization to support growth [19] - The company is exploring collaborations to enhance its product development and commercialization strategies [11]

Financial Data and Key Metrics Changes - The meeting reported that proxies were received for 961,887 of the 2,277,139 shares of common stock outstanding, representing approximately 42% of the total shares, which unfortunately does not constitute a quorum for business transactions [3]. Company Strategy and Development Direction - The company has adjourned the annual stockholders' meeting due to the lack of quorum, indicating a need for better engagement with shareholders to ensure future meetings can proceed as planned [4]. Other Important Information - The company will determine a new date and time to hold the 2025 annual stockholders' meeting, reflecting ongoing organizational and operational adjustments [4]. Q&A Session Summary - No questions or answers were recorded during this meeting as it was adjourned due to the lack of quorum, preventing any business transactions from taking place [3].

Financial Data and Key Metrics Changes - The meeting reported that proxies were received for 961,887 of the 2,277,139 shares of common stock outstanding, representing approximately 42% of the total shares, which unfortunately does not constitute a quorum for business transactions [3]. Company Strategy and Development Direction - The meeting was adjourned due to the lack of a quorum, and the company's board of directors will determine a new date and time for the 2025 annual stockholders' meeting, indicating ongoing strategic planning and governance [4]. Other Important Information - The company introduced its auditors and legal representatives at the meeting, highlighting the importance of transparency and compliance in corporate governance [1][2]. Summary of Q&A Session - No questions or answers were recorded during this meeting as it was adjourned due to the lack of quorum, preventing any business transactions from taking place [3][4].

Financial Data and Key Metrics Changes - The meeting reported that proxies were received for 961,887 of the 2,277,139 shares of common stock outstanding, representing approximately 42% of the total shares, which unfortunately does not constitute a quorum for business transactions [3]. Company Strategy and Development Direction - The company has adjourned the annual stockholders' meeting due to the lack of quorum, indicating a need for further engagement with shareholders to ensure participation in future meetings [4]. Other Important Information - The company will determine a new date and time to hold the 2025 annual stockholders' meeting, reflecting ongoing efforts to maintain communication with stakeholders [4]. Summary of Q&A Session - No questions or answers were recorded during this meeting as it was adjourned due to the lack of quorum [3][4].

Core Viewpoint - Xenetic Biosciences, Inc. announced the adjournment of its 2025 Annual Meeting of Stockholders due to a lack of quorum, urging stockholders who have not voted to participate in the reconvened meeting scheduled for January 8, 2026 [1][2]. Company Information - Xenetic Biosciences is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies aimed at treating difficult cancers [8][9]. - The company's proprietary DNase technology targets neutrophil extracellular traps (NETs) involved in cancer progression, with a focus on developing systemic DNase as an adjunctive therapy for pancreatic carcinoma and other solid tumors [8][9]. Meeting Details - The Annual Meeting was adjourned because fewer than a majority of the outstanding shares entitled to vote were present [2]. - The reconvened Annual Meeting will take place virtually on January 8, 2026, at 10:00 a.m. Eastern Time [2]. - Stockholders who have already voted do not need to vote again, as their previous votes will remain valid [3]. Voting Information - Stockholders eligible to vote must do so by 11:59 p.m. Eastern Time on January 7, 2026, and can vote online or by telephone [4]. - The record date for determining eligible stockholders remains October 15, 2025 [3][4]. Proxy Statement - A definitive proxy statement was filed with the SEC on October 31, 2025, and is available for stockholders to review [7].

Core Viewpoint - Xenetic Biosciences, Inc. has announced a 4-month extension of its collaboration with The Scripps Research Institute to advance its research program on combining systemic DNase I and CAR T-cell therapies for cancer treatment [1] Company Summary - The collaboration with Scripps Research and Dr. Alexey Stepanov is effective from November 1, 2025 [1] - Xenetic's systemic DNase I candidate, XBIO-015, is currently in preclinical development [1] - The focus of the development is on the combination of XBIO-015 with CAR-T cell therapy for both hematologic and solid tumors [1]

Financial Performance - Xenetic Biosciences, Inc. reported financial results for the three months ended September 30, 2025[6]. - The company issued a press release on November 13, 2025, detailing its performance metrics[6]. - Specific financial figures and performance indicators are included in the press release, which is referenced as Exhibit 99.1[9]. - The report does not provide detailed numerical data or specific performance percentages in the available content[6][8]. - The company’s financial statements and additional exhibits are filed with the SEC[9]. Future Outlook - Forward-looking statements indicate expectations for future performance, subject to various risks and uncertainties[8]. - The company is subject to market factors and economic conditions that may impact its operations and results[8]. Product and Market Development - The company has not indicated any new product developments or market expansions in the provided documents[8]. - There is no mention of mergers or acquisitions in the current report[8]. Signatory Information - The report is signed by James Parslow, Interim Chief Executive Officer and Chief Financial Officer[13].

Core Viewpoint - Xenetic Biosciences, Inc. is focused on advancing innovative immuno-oncology technologies to address difficult-to-treat cancers, highlighting progress in their systemic DNase I program in combination with established cancer therapies [1] Financial Performance - The company reported net proceeds of approximately $3.9 million from an offering in October 2025 [1] - Financial results for the third quarter of 2025 were disclosed, indicating ongoing financial activities [1] Strategic Initiatives - Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners is emphasized, indicating a commitment to building partnerships in the oncology field [1] - The company aims to build a foundation for potentially transformative progress in the oncology treatment paradigm [1]

Financial Performance - Total revenue for Q3 2025 was $1,026,957, representing a 67.3% increase from $614,243 in Q3 2024[12] - Royalty revenue for the nine months ended September 30, 2025, was $2,210,115, up from $1,851,464 in the same period of 2024, indicating a growth of 19.4%[12] - Net loss for Q3 2025 was $509,940, compared to a net loss of $436,671 in Q3 2024, showing a decline of 16.7%[12] - For the nine months ended September 30, 2025, the company reported a net loss of $2,101,784, an improvement from a net loss of $2,905,754 in the same period of 2024, representing a decrease of approximately 27.7%[26] - Revenue for the nine months ended September 30, 2025, was $2,210,115, an increase of 19.4% compared to $1,851,464 for the same period in 2024[38] - Royalty revenue for the quarter ended September 30, 2025 increased by 67.2% to approximately $1.0 million from $0.6 million in the same quarter of 2024[76] - For the nine months ended September 30, 2025, royalty revenue increased by 19.4% to approximately $2.2 million from approximately $1.9 million in the same period of 2024[82] Operating Costs and Expenses - Total operating costs and expenses for Q3 2025 were $1,571,691, compared to $1,113,716 in Q3 2024, reflecting an increase of 41.2%[12] - Research and development expenses for the nine months ended September 30, 2025, were $2,292,068, slightly up from $2,246,077 in the same period of 2024[12] - Research and development expenses for the quarter ended September 30, 2025 rose by 105.6% to approximately $0.8 million compared to $0.4 million in the prior year[77] - General and administrative expenses for the quarter ended September 30, 2025 increased by 9.3% to approximately $0.8 million from approximately $0.7 million in the comparable quarter in 2024[78] - General and administrative expenses for the nine months ended September 30, 2025 decreased by 21.4% to approximately $2.1 million from approximately $2.7 million in the comparable period in 2024[84] Cash and Assets - Cash and cash equivalents decreased to $4,121,599 as of September 30, 2025, down from $6,165,568 as of December 31, 2024, a decline of 33.1%[10] - Total assets decreased to $5,067,960 as of September 30, 2025, from $6,901,443 as of December 31, 2024, a reduction of 26.5%[10] - Total stockholders' equity fell to $3,956,185 as of September 30, 2025, down from $6,007,180 as of December 31, 2024, a decrease of 34.1%[10] - The company's cash at the end of the period was $4,121,599, down from $6,839,560 at the end of the same period in 2024, reflecting a decrease of approximately 39.5%[26] - As of September 30, 2025, the company had approximately $4.1 million in cash and $1.1 million in current liabilities, compared to $6.2 million in cash and $0.9 million in current liabilities at December 31, 2024[88] Capital and Funding - The company has raised approximately $3.9 million in an underwritten offering of common stock subsequent to the quarter end[32] - The company anticipates needing additional capital in the long term to pursue its business initiatives despite having adequate resources for at least the next twelve months[32] - The company raised approximately $3.9 million in an underwritten offering of common stock subsequent to the quarter end, indicating ongoing efforts to secure additional capital[89] Strategic Initiatives - The company is engaged in a formal strategic review process to explore alternatives to maximize shareholder value, including potential sales or business combinations[33] - The company is advancing its proprietary DNase technology as an adjunctive therapy for pancreatic carcinoma and metastatic solid tumors[70] Legal and Compliance - The company is not currently subject to any material legal proceedings, which may positively impact its financial stability[102] - There have been no material changes to the risk factors previously disclosed, suggesting stability in the company's risk environment[103] - The company’s management has concluded that its disclosure controls and procedures are effective, ensuring compliance with SEC requirements[99] Other Financial Information - Interest income for the nine months ended September 30, 2025, was $104,205, down from $197,994 in the same period of 2024, a decrease of 47%[12] - The valuation allowance against deferred tax assets was approximately $41.7 million as of September 30, 2025[58] - Total share-based expense related to stock options and RSUs was approximately $16,000 for the three months ended September 30, 2025[54] - The Company had warrants to purchase approximately 800 shares of common stock outstanding as of September 30, 2025, with an exercise price of $29.09 per share[53] - No amounts were recognized as revenue related to the Serum Institute, Pharmsynthez, or SynBio agreements during the three and nine months ended September 30, 2025[50] - The Company has no unrecognized tax positions as of September 30, 2025[59] - The Company did not grant any stock options or RSUs during the three and nine months ended September 30, 2025[56] - The Company paid Dr. Genkin approximately $0.1 million during the three months ended September 30, 2025, related to consulting services[61] - The Company incurred program expenses of $2,271,998 for the nine months ended September 30, 2025, which is an increase of 43.7% from $1,581,070 in the same period of 2024[38] - Working capital decreased to approximately $4.0 million at September 30, 2025, down from approximately $5.7 million at December 31, 2024[87] - Cash flows used in operating activities for the nine months ended September 30, 2025 totaled approximately $2.0 million, slightly improved from $2.1 million for the same period in 2024[90] - There were no cash flows from investing or financing activities for the nine months ended September 30, 2025 and 2024, indicating a lack of investment or financing initiatives during this period[91][92] - The company has not experienced any material changes in contractual obligations and commitments as of September 30, 2025, compared to previous disclosures[93] - There are no off-balance sheet financing arrangements that could materially affect the company's financial condition[94]